LONDON, March 21, 2014 /PRNewswire/ --
The trading session on Thursday, March
20, 2014 ended on a positive note as the Dow Jones
Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ
Composite closed at 4,319.29, up 0.27%. The S&P 500 finished
the session 0.60% higher at 1,872.01. The gains were broad based as
nine out of ten sectors ended the session in positive. The S&P
500 Health Care Sector Index finished the day at 686.29, down
0.02%, whereas, the index has advanced 0.77% in the last one month.
Investor-Edge has initiated coverage on the following equities:
Zoetis Inc. (NYSE: ZTS), Mylan Inc. (NASDAQ: MYL), AVANIR
Pharmaceuticals Inc. (NASDAQ: AVNR) and Actavis PLC (NYSE: ACT).
Free technical research on ZTS, MYL, AVNR and ACT can be downloaded
upon signing up at:
http://www.investor-edge.com/398-register
On Thursday, Zoetis Inc.'s stock edged 0.60% higher, finishing the
session at $30.09. The stock recorded
trading volume of 3.67 million shares as compared to a three months
average volume of 4.49 million shares. The stock fluctuated between
$29.67 and $30.11 during the session.
Shares of the company traded at a PE ratio of 22.09. Zoetis Inc.'s
stock has advanced 2.42% in the previous three trading sessions and
0.40% in the last one month, while the same has declined 7.95% on
YTD basis. The stock is trading below its 50-day and 200-day moving
averages. Zoetis Inc.'s 200-day moving average of $31.12 is above the 50-day moving average of
$30.65. Moreover, the stock is
trading at a Relative Strength Index (RSI) of 46.37. Sign up today
to read free research on ZTS at:
http://www.investor-edge.com/398-ZTS-.pdf
Mylan Inc.'s stock reported a trading volume of 4.51 million
shares, as compared with a three months average volume of 4.16
million shares. The stock ended the day at $52.61, down 1.29% and at an intraday range of
$52.02 and $53.08. Shares of the company traded at a PE
ratio of 28.50. Mylan Inc.'s shares have fallen by 1.70% in the
previous three trading sessions, but they have advanced 0.67% in
the last one month and 21.22% on YTD basis. The stock is trading
above its 50-day and 200-day moving averages. Mylan Inc.'s 50-day
moving average of $48.67 is above the
200-day moving average of $40.15.
Furthermore, the stock is trading at an RSI of 56.44. Sign up today
to read free research on MYL at:
http://www.investor-edge.com/398-MYL-.pdf
On Thursday, shares in AVANIR Pharmaceuticals Inc. stock surged
3.24% to close at $4.14. A total of
1.82 million shares were traded, which is below the three months
average volume of 2.38 million. The stock oscillated between
$3.87 and $4.23 during the trading
session. AVANIR Pharmaceuticals Inc.'s shares have gained 6.98% in
the previous three trading sessions, 2.22% in the last one month,
and 23.21% on YTD basis. The stock is trading above its 50-day
moving average. AVANIR Pharmaceuticals Inc.'s 200-day moving
average of $4.25 is trading above the
50-day moving average of $3.85.
Furthermore, the stock is trading at an RSI of 49.10. Sign up today
to read free research on AVNR at:
http://www.investor-edge.com/398-AVNR-.pdf
Actavis PLC's stock recorded a trading volume of 1.61 million
shares, as compared with a three months average volume of 2.31
million shares. The stock ended the day at $215.72, down 0.35% after vacillating between
$214.18 and $218.73. Shares of the company traded at a PE
ratio of 62.43. Actavis PLC's shares have fallen by 2.11% in the
last one month, but they have advanced 0.71% in the previous three
trading sessions and 28.40% on YTD basis. Further, the company's
stock is trading above its 50-day and 200-day moving averages.
Actavis PLC's 50-day moving average of $198.51 is above the 200-day moving average of
$156.53. Additionally, shares of the
company are trading at an RSI of 57.82. Sign up today to read free
research on ACT at:
http://www.investor-edge.com/398-ACT-.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge